Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Snapshot of some VERY long term Trogarzo users

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Feb 10, 2021 10:21am

92 Views

Post# 32524339

RE:Snapshot of some VERY long term Trogarzo users

Good find as per UK with a conservative administration I am not shocked also they are hit by covid19 badly so NHS is quite restrained at the moment, the company can now instead try to launch Trogarzo in other European Union countries.

qwerty22 wrote: The virological rationale for the drug is solid.

https://www.researchgate.net/publication/348173483_1027_Long-Term_Efficacy_Safety_and_Durability_of_Ibalizumab-Based_Regimens_in_Subgroup_of_TMB-202_Participants

"Conclusion : Data from 12 patients who received IBA for an average of 9 years validate the long-term efficacy and safety of IBA in TE patients. Importantly, for most patients, the durability of virologic response was maintained with minimal adjustments to the OBR. Altogether, these data demonstrate the contribution of IBA towards durable viral suppression in TE HIV patients with limited therapeutic options."